Elixir Reports 79% Improvement In Lorelle-3H Flow, But Well Obstruction Halts Testing
EXR: $0.059 +3.51% · MC: $120M
After a 60-day soak, Lorelle-3H’s equivalent 12-hour flow rates improved 79% from the first testing phase, while stimulation-fluid flowback fell 85%; testing is paused as Elixir mobilises equipment to clear a debris blockage. Elixir also received its approximately $12 million R&D refund and repaid its R&D debt facility, leaving a net cash inflow of approximately $2 million.

Comments